Clinical treatment strategy and follow-up of lymphoepithelioma-like carcinoma: a retrospective study
Aim: To investigate the clinical features, diagnosis and treatment of lymphoepithelioma-like carcinoma (LELC).Materials & methods: The clinical data of 114 LELC patients were retrospectively analyzed.Results: Ninety-eight patients (86.0%) were Epstein-Barr virus-encoded small RNA (EBER) positive...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2024-12-01
|
| Series: | Future Science OA |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/20565623.2024.2384878 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1839627425762246656 |
|---|---|
| author | Shilong Zhang Yufu Lin Zhiyong Li Zhiming Wang Rongkui Luo Xiuping Zhang |
| author_facet | Shilong Zhang Yufu Lin Zhiyong Li Zhiming Wang Rongkui Luo Xiuping Zhang |
| author_sort | Shilong Zhang |
| collection | DOAJ |
| description | Aim: To investigate the clinical features, diagnosis and treatment of lymphoepithelioma-like carcinoma (LELC).Materials & methods: The clinical data of 114 LELC patients were retrospectively analyzed.Results: Ninety-eight patients (86.0%) were Epstein-Barr virus-encoded small RNA (EBER) positive detected by situ hybridization. A 67.1% (51/76) patients had PD-L1 expression. The 5-year overall survival rate of EBER negative patients was 51.6% while the rate of positive patients was 84.8% (p = 0.015). The 5-year progression free survival rate of EBER negative patients was 40.2% while the rate of positive patients was 70.2% (p = 0.004).Conclusion: The progression of LELC is relatively slow and present a better prognosis. The occurrence of tumor is closely related to Epstein–Barr virus infection and PD-L1 is highly expressed in tumor cells. |
| format | Article |
| id | doaj-art-304f6f3fb0b842c1a0d9b06a68c02d39 |
| institution | Matheson Library |
| issn | 2056-5623 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Future Science OA |
| spelling | doaj-art-304f6f3fb0b842c1a0d9b06a68c02d392025-07-16T11:42:32ZengTaylor & Francis GroupFuture Science OA2056-56232024-12-0110110.1080/20565623.2024.2384878Clinical treatment strategy and follow-up of lymphoepithelioma-like carcinoma: a retrospective studyShilong Zhang0Yufu Lin1Zhiyong Li2Zhiming Wang3Rongkui Luo4Xiuping Zhang5Department of Medical Oncology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, ChinaDepartment of Medical Oncology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, ChinaDepartment of Medical Oncology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, ChinaDepartment of Medical Oncology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, ChinaDepartment of Pathology, Zhongshan Hospital, Fudan University, Shanghai, ChinaDepartment of Medical Oncology, Zhongshan Hospital (Xiamen), Fudan University, Xiamen, ChinaAim: To investigate the clinical features, diagnosis and treatment of lymphoepithelioma-like carcinoma (LELC).Materials & methods: The clinical data of 114 LELC patients were retrospectively analyzed.Results: Ninety-eight patients (86.0%) were Epstein-Barr virus-encoded small RNA (EBER) positive detected by situ hybridization. A 67.1% (51/76) patients had PD-L1 expression. The 5-year overall survival rate of EBER negative patients was 51.6% while the rate of positive patients was 84.8% (p = 0.015). The 5-year progression free survival rate of EBER negative patients was 40.2% while the rate of positive patients was 70.2% (p = 0.004).Conclusion: The progression of LELC is relatively slow and present a better prognosis. The occurrence of tumor is closely related to Epstein–Barr virus infection and PD-L1 is highly expressed in tumor cells.https://www.tandfonline.com/doi/10.1080/20565623.2024.2384878Epstein–Barr (EB) viruslymphoepithelioma-like carcinomaprognosisPD-L1retrospective studytreatment |
| spellingShingle | Shilong Zhang Yufu Lin Zhiyong Li Zhiming Wang Rongkui Luo Xiuping Zhang Clinical treatment strategy and follow-up of lymphoepithelioma-like carcinoma: a retrospective study Future Science OA Epstein–Barr (EB) virus lymphoepithelioma-like carcinoma prognosis PD-L1 retrospective study treatment |
| title | Clinical treatment strategy and follow-up of lymphoepithelioma-like carcinoma: a retrospective study |
| title_full | Clinical treatment strategy and follow-up of lymphoepithelioma-like carcinoma: a retrospective study |
| title_fullStr | Clinical treatment strategy and follow-up of lymphoepithelioma-like carcinoma: a retrospective study |
| title_full_unstemmed | Clinical treatment strategy and follow-up of lymphoepithelioma-like carcinoma: a retrospective study |
| title_short | Clinical treatment strategy and follow-up of lymphoepithelioma-like carcinoma: a retrospective study |
| title_sort | clinical treatment strategy and follow up of lymphoepithelioma like carcinoma a retrospective study |
| topic | Epstein–Barr (EB) virus lymphoepithelioma-like carcinoma prognosis PD-L1 retrospective study treatment |
| url | https://www.tandfonline.com/doi/10.1080/20565623.2024.2384878 |
| work_keys_str_mv | AT shilongzhang clinicaltreatmentstrategyandfollowupoflymphoepitheliomalikecarcinomaaretrospectivestudy AT yufulin clinicaltreatmentstrategyandfollowupoflymphoepitheliomalikecarcinomaaretrospectivestudy AT zhiyongli clinicaltreatmentstrategyandfollowupoflymphoepitheliomalikecarcinomaaretrospectivestudy AT zhimingwang clinicaltreatmentstrategyandfollowupoflymphoepitheliomalikecarcinomaaretrospectivestudy AT rongkuiluo clinicaltreatmentstrategyandfollowupoflymphoepitheliomalikecarcinomaaretrospectivestudy AT xiupingzhang clinicaltreatmentstrategyandfollowupoflymphoepitheliomalikecarcinomaaretrospectivestudy |